Celgene Corporation (CELGZ) stock prices updated...
 

Celgene Corporation stock price, CELGZ

Celgene Corporation stock chart:



Celgene Corporation close price: 1.09

Stock price forecast:

DOWN TO -5.50%
Target: 1.03

Total forecasts: 75
Reached: 48 (64.00%)

Total Win: 2.16 (193.87%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90764863.16%2.162.55%30.29-0.01-0.03%2.152.59%
3031619.35%0.140.42%27.000.090.33%0.230.69%
1415426.67%0.100.64%11.86-0.03-0.25%0.070.44%
78337.50%0.091.08%5.37-0.08-1.49%0.010.12%

Showing 1-10 of 382 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-03-251.091.030000-00-00
2017-03-241.071.030000-00-00
2017-03-231.071.070000-00-00
2017-03-221.071.070000-00-00
2017-03-211.071.060000-00-00
2017-03-201.041.072017-03-24
2017-03-191.041.072017-03-24
2017-03-181.041.072017-03-24
2017-03-171.071.082017-03-24
2017-03-161.061.110000-00-00

Celgene Corporation latest news:


  • 03/01/2017 14:46:10

    Juno Therapeutics stock declines 4% after decision to not move forward with cancer drug

    Juno Therapeutics Inc. stock declined as much as 4% after the bell on Wednesday after the company said it won't be moving forward with its JCAR015 drug, which is intended for relapsed or refractory acute lymphoblastic leukemia, saying it recognizes the "unfortunate and unexpected toxicity" of the drug. The company also reported fourth-quarter earnings. Several patients died during clinical trials last year in the summer and then the fall. The company initially attributed the deaths to the chemotherapy drug used with JCAR015, which it removed from the trial, but then two additional patients died, the company said in late November. The company said its investigation found that certain patient, product and other characteristics may have added to the trial's risk. Changes could allow the trial to proceed, Juno said, but it would require another phase 1 trial. As such, Juno said it, along with partner Celgene Corp. , made the "strategic decision" to focus resources on another drug in this disease area, with a trial planned for next year. Juno shares have increased 27.2% over the last three months, compared with a 9.4% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/26/2017 08:38:14

    Celgene's 2% share decline may be due to disappointing 2020 guidance, analyst says

    Celgene Corp. shares, which declined 2.4% in morning trade, may be sliding because investors hoped the company would raise its 2020 guidance today, Evercore ISI analyst Mark Schoenebaum said Thursday. Celgene officially reported fourth-quarter earnings Thursday, but the company had announced guidance earlier this month. Based on "bullish" statements by company management at the J.P. Morgan Health Care conference in mid-January, "some folks thought that CELG might officially raise their 2020 guidance today," Schoenebaum said, cautioning that he can't be sure that contributed to the decline. But "this is classic CELG stock behavior around quarterly results," he said. "There seems to always be a pre-call thesis out there that they'll raise guidance." The company may have said it can grow EPS every year from 2020 to 2030 but that "would be a remarkable accomplishment," he said. Celgene shares have risen 13.3% over the last three months, compared with a 7.5% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/20/2017 06:31:02

    Celgene Could Jump 22%

    In the last three months, shares of Celgene (CELG) are up nearly 14%. The stock jumped after the third-quarter earnings report on Oct. 27. Then, last week, at the J.P. Morgan Healthcare Conference, Celgene (CELG) reported preliminary fourth-quarter and fiscal 2016 year-end results.

  • 01/09/2017 10:01:02

    Celgene Raises 2017 Guidance, Shares Fall Anyway

    Celgene(CELG) shares are falling despite the fact that the company raised 2017 revenue and profit projections while at the J.P. Morgan Healthcare Conference. The Summit, N.J.-based biotech company, which is focused on multiple myeloma drug, Revlimid, announced Monday that it was raising revenue and profit projections for 2017, which it had previously set in October.

  • More trends:

    Celladon CorporationCLDN | Celldex Therapeutics, Inc.CLDX | Cellectar Biosciences, Inc.CLRB | Cellectar Biosciences, Inc.CLRBW | Cellectis S.A.CLLS | Cellular Biomedicine Group, Inc.CBMG | Celsion CorporationCLSN | Celsus Therapeutics PlcCLTX | Celyad SACYAD | Cempra, Inc.CEMP |